Information contributed by meta-analysis in exposure-response modeling: Application to phase 2 dose selection of guselkumab in patients with moderate-to-severe psoriasis

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 41, Issue 3, 2014, Pages 239-250

  Hu, Chuanpu ^a   Wasfi, Yasmine ^a   Zhuang, Yanli ^a   Zhou, Honghui ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Clinical drug development; NONMEM; Population pharmacokinetic pharmacodynamic modeling

Indexed keywords

GUSELKUMAB; PLACEBO; MONOCLONAL ANTIBODY;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; HUMAN; IC 50; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; SENSITIVITY ANALYSIS; CLINICAL TRIAL; DOSE RESPONSE; META ANALYSIS (TOPIC); PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL (TOPIC); POPULATION; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS, PHASE II AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; META-ANALYSIS AS TOPIC; MODELS, STATISTICAL; POPULATION; PSORIASIS;

EID: 84904213649     PISSN: 1567567X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/s10928-014-9360-6     Document Type: Article

References (20)

1. Koo J (1996) Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 14(3):485-496
2. Krueger GG, Duvic M (1994) Epidemiology of psoriasis: clinical issues. J Invest Dermatol 102(6):14S-18S (Pubitemid 24210359)
3. Schon MP, Boehncke WH (2005) Psoriasis. N Engl J Med 352(18):1899-1912 (Pubitemid 40627816)
4. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, McClanahan T, Kastelein RA, Cua DJ (2005) IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201(2):233-240 (Pubitemid 40189432)
5. Rozenblit M, Lebwohl M (2009) New biologics for psoriasis and psoriatic arthritis. Dermatol Ther 22(1):56-60
6. Yawalkar N, Karlen S, Hunger R, Brand CU, Braathen LR (1998) Expression of interleukin-12 is increased in psoriatic skin. J Invest Dermatol 111(6):1053-1057 (Pubitemid 29115174)
7. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon KB (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-weeks results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371(9625):1665-1674 (Pubitemid 351671883)
8. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, Dooley LT, Reich K (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-weeks results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371(9625):1675-1684 (Pubitemid 351671884)
9. Zhu Y, Hu C, Lu M, Liao S, Marini JC, Yohrling J, Yeilding N, Davis HM, Zhou H (2009) Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol 49(2):162-175
10. Zhou H, Hu C, Zhu Y, Lu M, Liao S, Yeilding N, Davis HM (2010) Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis. J Clin Pharmacol 50(3):257-267
11. Hu C, Szapary PO, Yeilding N, Davis HM, Zhou H (2011) Informative dropout modeling of longitudinal ordered categorical data and model validation: application to exposure-response modeling of physician's global assessment score for ustekinumab in patients with psoriasis. J Pharmacokinet Pharmacodyn 38(2):237-260
12. Hu C, Yeilding N, Davis HM, Zhou H (2011) Bounded outcome score modeling: application to treating psoriasis with ustekinumab. J Pharmacokinet Pharmacodyn 38(4):497-517
13. Sofen H, Smith S, Matheson RT, Leonardi CL, Calderon C, Brodmerkel C, Li K, Campbell K, Marciniak JS, Wasfi Y, Wang Y, Szapary P, Krueger J (2014) Guselkumab (interleukin-23-specific monoclonal antibody) demonstrates clinical and molecular response in moderate-to-severe psoriasis (2014). J Allergy Clin Immunol 133(4):1032-1040
14. Menter MA, Krueger GC, Feldman SR, Weinstein GD (2003) Psoriasis treatment 2003 at the new millennium: position paper on behalf of the authors. J Am Acad Dermatol 49(2 Suppl):S39-S43 (Pubitemid 36951245)
15. Ashcroft DM, Wan Po AL, Williams HC, Griffiths CE (1999) Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol 141(2):185-191 (Pubitemid 29397982)
16. Beal SL, Sheiner LB, Boeckmann A, Bauer RJ (2009) NONMEM User's Guides (1989-2009). Icon Development Solutions, Ellicott City
17. Dayneka NL, Garg V, Jusko WJ (1993) Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 21(4):457-478 (Pubitemid 24025269)
18. Hu C, Xu Z, Mendelsohn A, Zhou H (2013) Latent variable indirect response modeling of categorical endpoints representing change from baseline. J Pharmacokinet Pharmacodyn 40(1):81-91
19. West GB, Brown JH, Enquist BJ (1997) A general model for the origin of allometric scaling laws in biology. Science 276:122-126 (Pubitemid 27161259)
20. Food and Drug Administration (2004) Critical Path Opportunity List. http://www.fda.gov/oc/initiatives/criticalpath/projectsummary/consortium.html. Accessed 19 May 2014